Idorsia Past Earnings Performance
Past criteria checks 0/6
Idorsia's earnings have been declining at an average annual rate of -16.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 6.2% per year.
Key information
-16.1%
Earnings growth rate
-7.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 6.2% |
| Return on equity | n/a |
| Net Margin | -202.5% |
| Next Earnings Update | 21 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Idorsia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 185 | -374 | 451 | 0 |
| 30 Jun 23 | 126 | -814 | 524 | 0 |
| 31 Mar 23 | 113 | -843 | 529 | 0 |
| 31 Dec 22 | 97 | -828 | 507 | 0 |
| 30 Sep 22 | 48 | -887 | 474 | 0 |
| 30 Jun 22 | 44 | -810 | 391 | 0 |
| 31 Mar 22 | 34 | -728 | 302 | 0 |
| 31 Dec 21 | 35 | -635 | 230 | 0 |
| 30 Sep 21 | 36 | -520 | 161 | 0 |
| 30 Jun 21 | 27 | -499 | 131 | 0 |
| 31 Mar 21 | 74 | -429 | 109 | 0 |
| 31 Dec 20 | 72 | -445 | 97 | 0 |
| 30 Sep 20 | 70 | -450 | 81 | 0 |
| 30 Jun 20 | 69 | -451 | 71 | 0 |
| 31 Mar 20 | 22 | -507 | 69 | 0 |
| 31 Dec 19 | 24 | -494 | 65 | 0 |
| 30 Sep 19 | 61 | -460 | 62 | 0 |
| 30 Jun 19 | 61 | -459 | 62 | 0 |
| 31 Mar 19 | 61 | -414 | 61 | 0 |
| 31 Dec 18 | 61 | -386 | 59 | 0 |
| 30 Sep 18 | 209 | -213 | 65 | 0 |
| 30 Jun 18 | 203 | -165 | 62 | 0 |
| 31 Dec 17 | 190 | -17 | 36 | 0 |
Quality Earnings: IDRS.F is currently unprofitable.
Growing Profit Margin: IDRS.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDRS.F is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare IDRS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDRS.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IDRS.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.